Ivax, BMS Suit Up In Taxol Legal Battle.(Brief Article)

Chemical Market Reporter, August, 2000 by BOSWELL, CLAY

IVAX CORPORATION and Bristol-Myers Squibb are suiting up for yet another legal battle over a generic version of BMS's anticancer drug Taxol (paclitaxel). The current issue involves an effort by BMS to delay the entry of generic paclitaxel through a listing in Food and Drug Administration's so-called Orange Book.

Last week, Bristol-Myers Squibb reported that it had complied with a temporary restraining order from a federal district court brought against BMS by American BioScience Inc. (ABI). BMS had listed an ABI patent, issued on August 1, which covered a range of single unit dosage forms of paclitaxel in FDA's Orange Book, which lists approved drug products with therapeutic equivalence. BMS says if ABI's patent remains listed in the Orange Book, and...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.